Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
View Patent ↗Methods, pharmaceutical compositions, and compounds for reducing body weight, modulating body lipid metabolism, and reducing food intake in mammals are provided. The compounds of the invention include fatty acid ethanolamide compounds, homologues and analogs of which the prototype is the endogenous fatty acid ethanolamide, oleoylethanolamide.
1. A method of reducing food intake in a mammal in need thereof, said method comprising administering to said mammal a fatty acid alkanolamide in an effective amount to reduce food intake in said mammal, wherein the fatty acid alkanolamide is a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 5; a and b are each an integer wherein the sum of a and b is from 0 to 4; and R 1 is hydrogen and R 2 is selected from the group consisting of hydrogen, unsubstituted (C 1 -C 6 ) alkyl, and unsubstituted (C 2 -C 6 ) acyl, and wherein optionally up to four hydrogen atoms of the fatty acid portion and alkanolamide portion of the formula are substituted by methyl or a double bond joining adjacent carbons of the formula, and additionally the bond between carbons c and d may be unsaturated or saturated.
2. The method according to claim 1 , wherein the fatty acid alkanolamide is oleoylethanolamide.
3. The method of claim 1 , wherein n is 1.
4. The method of claim 1 , wherein the fatty acid portion is monounsaturated.
5. The method of claim 1 , wherein the administering is via a dermal patch.
6. The method of claim 4 , wherein the fatty acid portion is oleic acid.
7. The method of claim 3 , wherein the fatty acid portion is selected from the group consisting of elaidic acid, palmitoleic acid, palmitic acid, linoleic acid, aipha-linolenic acid, and gamma-linolenic acid.
8. The method of claim 3 , wherein n is 1 and R 2 is a lower (C 1 -C 3 ) alkyl.
9. The method of claim 3 , wherein n is 1 and R 2 is straight or branched (C 2 -C 6 ) acyl.
10. The method according to claim 1 , wherein the mnammal is human.
11. The method according to claim 1 , wherein the fatty acid alkanolamide is palmitoylethanolamide.
12. The method according to claim 1 , wherein said fatty acid alkanolamide is administered with a pharmaceutically acceptable carrier by an oral, rectal, topical, or parenteral route.
13. The method of claim 1 , wherein a dose of the fatty acid alkanolamide in an amount from about 10 mg to 1000 mg of the fatty acid alkanolamide is administered.
14. The method of claim 1 , wherein a dose of about 1 mg to 100 mg of the fatty acid alkanolaniide is administered.
15. The method of claim 1 , wherein a dose of about 100 mg to 500 mg of the fatty acid alkanolamide is administered.
16. The method of claim 1 , wherein the fatty acid alkanolamide is administered in a unit dose format.
17. The method of claim 1 , wherein the fatty acid alkanolamide is administered orally.
18. The method of claim 1 , wherein the fatty acid alkanolamide is orally administered in a tablet, pill, or capsule form.
19. The method of claim 1 , wherein the administering is topical.
20. A method of reducing food intake in a mammal in need thereof, said method comprising administering to said mammal in an effective amount to reduce body fat or body weight, a compound of the formula:
or a pharmaceutically acceptable salt thereof, wherein n is an integer from 1 to 5; a and b are each an integer wherein the sum of a and b is from 0 to 4; and R 1 is hydrogen and R 2 is selected from the group consisting of hydrogen, unsubstituted (C 1 -C 6 ) alkyl, and unsubstituted (C 2 -C 6 ) acyl, and wherein, optionally, up to four hydrogen atoms of the fatty acid portion and alkanolamide portion of the formula are substituted by methyl or a double bond joining adjacent carbons of the formula, and additionally the bond between carbons c and d may he unsaturated or saturated.
21. The method of claim 1 , wherein one of the hydrogen atoms of the fatty acid portion and alkanolamide portion of the compound is substituted by methyl.
22. The method of claim 21 , wherein the compound is selected from the group consisting of (R) 1 ′-methyloleoylethanolamide, (S)1′-methyloleoylethanolamide, (R)2′-methyloleoylethanolamide, (S)2′- methyloleoylethanolamide, (R)1-methyloleoylethanolamide, (S)1-methyloleoylethanolamide and the pharmaceutically acceptable salts thereof.
23. The method of claim 1 , wherein R 2 is —C(O)CH 2 CH 3 , —C(O)CH 2 CH 2 CH 3 , or —C(O)CH 3 .
24. The method of claim 1 , wherein n is 1 and R 2 is hydrogen.
25. The method of claim 7 , wherein n is 1 and R 2 is hydrogen.
26. The method of claim 2 , wherein the mammal is human.
27. The method of claim 1 , wherein R 2 is H.
28. The method of claim 1 , wherein the fatty acid alkanolamide is elaidylethanolamide.
29. The method of claim 1 , wherein there is a double bond between carbons c and d.
30. The method of claim 1 , wherein a=1, b=1.
31. The method of claim 1 , wherein a=1, b=1, and n=1.
32. The method of claim 29 , wherein the stereochemistry of the compound about the double bond is E.
33. The method of claim 29 , wherein the stereochemistry of the compound about the double bond is Z.
34. The method of claim 20 , wherein there is a double bond between carbons c and d.